See also this year's filing and all EDGAR filings for this company.
PDF Report 0000320017_2022_Lisata_Therapeutics_INC.pdf
Logs
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Assets', 'missing_ratio': 8.678415126370268e-07, 'aggregate_val': 63375682, 'exp_sum': 63375627, 'exp_to_value': {'IntangibleAssets': 0, 'AssetsNonCurrent': 1434077, 'AssetsCurrent': 61109645, 'PropertyPlantAndEquipment': 256905, 'remainder_Assets': 575000}} |
| info | Added remainder_ComprehensiveNetIncome directly from 10K | industry.us_generic | {} |
Graph
Absolute values for 0000320017, Lisata Therapeutics INC
| xvar | xval | |
|---|---|---|
| 0 | IntangibleAssets | 0 |
| 1 | AssetsNonCurrent | 764,000 |
| 2 | AssetsCurrent | 96,182,000 |
| 3 | PropertyPlantAndEquipment | 62,000 |
| 4 | remainder_Assets | 0 |
| 5 | LongTermLiabilities | 485,000 |
| 6 | LiabilitiesCurrent | 4,523,000 |
| 7 | remainder_Liabilities | 0 |
| 8 | LaborExpense | 0 |
| 9 | CostOfGoodsAndServicesSold | 0 |
| 10 | GeneralAndAdministrativeExpense | 11,370,000 |
| 11 | GoodwillImpairmentLoss | 0 |
| 12 | OperatingCostsAndExpenses | 0 |
| 13 | DepreciationDepletionAndAmortization | 0 |
| 14 | SellingAndMarketingExpense | 0 |
| 15 | ResearchAndDevelopmentExpense | 17,680,000 |
| 16 | remainder_Expenses | -1,508,000 |
| 17 | remainder_Revenues | 0 |
| 18 | remainder_NetIncome | 76,000 |
| 19 | remainder_ComprehensiveNetIncome | -57,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 97,008,000 |
| 1 | Liabilities | 5,008,000 |
| 2 | Expenses | 27,542,000 |
| 3 | Revenues | 0 |
| 4 | StockholdersEquity | 92,000,000 |
| 5 | NetIncome | -27,466,000 |
| 6 | ComprehensiveNetIncome | -27,523,000 |
| 7 | BaseVar | 64,845,500 |
| 8 | EconomicCapitalRatio | 4.47 |
Edgar->Model Mapping
Feature Distribution
Change over Time
